DOCSLIB.ORG

The Power of TRU COMPLIANCETM

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Power of TRU COMPLIANCETM The Power of TRU COMPLIANCETM Compliant. Actionable. Ethical. THE The Gold Standard of GOLD Medication Reviews STANDARD CoPs-Compliant Med Reviews. Complete evaluation of medication history. EPCS Certified for controlled substances. Detailed clinical insights with actionable recommendations. Reduces lost and unfilled prescriptions. Less risk of adverse drug Drug Utilization Review shows cost-effective interactions and reactions. $ alternatives, recommends discontinuation of non-palliative medications. Fewer prescribing and dispensing errors. Covered vs. Non-covered medications: We provide industry-best practices for hospice and palliative medication coverage. CMS Reporting Recommendations on drug effectiveness, side effect CR-8358 and 10573 imported into your risks vs. drug benefits, interactions, duplicate EMR via SFTP. therapies, and drug therapy concurrently associated with laboratory monitoring. Opioid laxative report. Adverse Drug Reaction Reports. HCPCS coding. Alerts for inappropriate coverage The 5 Rights to a by Medicare Part D. Medication Pass The Best = Outcome The Right For the At the With the Right In the Right Drug Right Patient Right Time Route of Dosage Form Administration Introducing: Tru360TM Tru Partnership. Tru Customization. Tru Service.TM Tru360 is the most comprehensive, hospice-centered, patient-focused solution in the market today. Tru360 drives sustained cost reduction while improving patient satisfaction and outcomes. Tru360 is built on five key components that produce excellent end-of-life care in a cost-effective manner. PARTNERSHIP EFFICIENCY Real Collaboration. Powered by People. Intuitive Workflow. Proactive Intervention. Driven by Data. Real Results. We build a custom service model to fit your Our technology provides proactive intervention, workflow and your culture. Your Tru360 Team, streamlines pharmacy interaction and saves up including a dedicated pharmacist and account to $2,000 per nurse annually. HPS pharmacists manager, partner with you to manage saving’s are available 24/7 so you never wait for the initiatives. The result: sustained and ongoing answers you need. We save you time, so you cost reduction to reinvest in growth – and can focus on patient care. we’ll be there for you every step of the way. EDUCATION COMPLIANCE Empowered Nurses. Seamless Onboarding. Compliant. Actionable. Ethical. Rapid Results. HPS is the Gold Standard for medication We provide industry news and resources reviews. Our CoPs-Compliant med reviews that affect you. Through CE Courses, our provide a complete evaluation of medication webinar series, news articles, blog posts, history, detailed clinical insights with custom live presentations and our actionable recommendations, and much extensive resource library we empower more to ensure that you provide the right your team to make the best decisions at medication to the right patient in the right the point of prescribing. form and dosage at the right time. NETWORK A Custom Network. Built for Hospice. Built for You. With 65,000 plus pharmacies in our network, we don’t force you into a one-size fits-all solution. HPS connects your hospice to a nationwide network of thousands of local delivery providers to ensure patients receive access to medications when they need them. 2201 N. Central Expressway Suite 250, Richardson, TX 75080 | 866.851.4866 HospicePharmacySolutions.com ©2019 Hospice Pharmacy Solutions. All rights reserved. HPS-0014-19-1-v6 The premiere, hospice-centered, patient-focused PBM..
Load more

Recommended publications
  • Hospice and Assisted Living: Improving Care at the End of Life
    Hospice and Assisted Living: Improving Care at the End of Life Cherry Meier, RN, MSN eniors have embraced the concept of “aging in place.” S The challenge that inevitably occurs is the concept of “dying in place.” Seniors do not want to go through another change in living arrangements and do not want to become a burden on their families at the end of their life. Is it realistic to think that an eld- erly resident may be able to die in an assisted living (AL) residence? Depending upon what state you live in, it may or may not be possi- ble. Some states have very strict move-in and discharge require- ments that prohibit a dying resident from staying in their AL residence because they become bedbound, have a foley catheter, or require oxygen. Such requirements are usu- ally in response to concerns for life and safety in the event that a build- ing needs to be evacuated quickly or that the resident has complex 6 months or less if the illness runs equipment, and medical supplies needs that cannot be met by the AL its normal course and elects to re- related to the terminal illness. staff. Other states waive these rules ceive palliative/comfort care instead • On-call services, 24 hours a day. for residents who elect to receive of curative care. The AL residence • Bereavement care to the family/ care from hospice. is considered to be the resident’s loved ones following the death home, where the following services of the resident. The Medicare Hospice Benefit can be provided: The Medicare Hospice Benefit is • Services by an interdisciplinary The goal of care is to control the available to Medicare and Medicaid health care team comprised of resident’s pain and other uncomfort- beneficiaries in all states, except physicians, nurses, home health able symptoms through the dying Oklahoma, New Hampshire, and aides, social workers, chaplains, process.
    [Show full text]
  • Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2013 Annual Report Prescription Drug Fee for Service Programs
    Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2013 Annual Report Prescription Drug Fee For Service Programs December 2014 Executive Summary of 2013 State Medicaid DUR Annual Reports Each State Medicaid program under Section 1927 (g) (3) (D) of the Social Security Act (the Act) is required to submit an annual report on the operation of its Medicaid Drug Utilization Review (DUR) program. States are required to report on their state’s prescribing patterns, cost savings generated from their DUR programs and their programs’ operations, including adoption of new innovative DUR practices. DUR is a two-phase process that is conducted by the Medicaid state agencies. In the first phase (Prospective DUR - ProDUR) the state’s Medicaid agency’s electronic monitoring system screens prescription drug claims to identify problems such as therapeutic duplication, drug-disease contraindications, incorrect dosage or duration of treatment, drug allergy and clinical misuse or abuse. The second phase (Retrospective DUR -RetroDUR) involves ongoing and periodic examination of claims data to identify patterns of fraud, abuse, gross overuse, or medically unnecessary care and implements corrective action when needed. On May 19th, 2014 CMS sent the states the newly revised Medicaid DUR Annual Report Survey to complete. The new survey included a significantly-expanded Fraud, Waste and Abuse section, new questions about Prescription Drug Monitoring Programs (PDMP) section and inquiries regarding state Managed Care Organizations (MCOs). Below is a brief summary of the findings. I. Demographics – Page 1 All states and the District of Columbia submitted a 2013 Medicaid DUR Annual Report, with the exception of Arizona because almost all of its beneficiaries are enrolled in MCOs.
    [Show full text]
  • Self-Care for the Hospice Professional by Sally Hill Jones, Phd, LCSW
    A Delicate Balance: Self-Care For the Hospice Professional By Sally Hill Jones, PhD, LCSW Cindy, an experienced hospice professional, approached me one Monday morning, saying, “I think I’m losing it. Just the thought of seeing my patients today is too much.” She then described taking repeated showers but feeling that she still had the “smell of death” on her afterward. There had been an unusual number of deaths during her weekend on call, and as she named her patients, she began to cry. We devised a plan to begin her emotional processing that included taking the day off, journaling, talking to others she trusts, and saying good-bye to her patients. Service to individuals at the end of life and their families is an experience rich with meaning. Some important tasks can be accomplished only at life’s end, providing the opportunity for life review, healing, and coming to terms with one’s legacy. It is a time of potentially profound emotions and spiritual connections, letting go of the physical self and embracing the intangible inheritance left behind. To be involved professionally at this crucial time is deeply rewarding and yet demanding. Hospice staff regularly experience a wide range of powerful emotions, the mystical space between the physical and spiritual worlds, and the reality of loss and death. End-of-life experiences range from inspiring, graceful processes to difficult, complex situations with layers of long-standing problems, few resources, and the potential for abuse or suicide. Given the scope and intensity of hospice work, thoughtful, intentional focus on self-care is necessary for hospice professionals to remain effective.
    [Show full text]
  • Pharmacist's Role in Palliative and Hospice Care
    456 Medication Therapy and Patient Care: Specific Practice Areas–Guidelines ASHP Guidelines on the Pharmacist’s Role in Palliative and Hospice Care Palliative care arose from the modern hospice movement and and in advanced clinical practice (medication therapy man- has evolved significantly over the past 50 years.1 Numerous agement services, pain and symptom management consulta- definitions exist to describe palliative care, all of which fo- tions, and interdisciplinary team participation). cus on aggressively addressing suffering. The World Health Organization and the U.S. Department of Health and Human Purpose Services both stipulate the tenets of palliative care to include a patient-centered and family-centered approach to care, In 2002, ASHP published the ASHP Statement on the with the goal of maximizing quality of life while minimiz- Pharmacist’s Role in Hospice and Palliative Care.28 These 2 ing suffering. In its clinical practice guidelines, the National guidelines extend beyond the scope of that statement and Consensus Project for Quality Palliative Care of the National are intended to define the role of the pharmacist engaged in Quality Forum (NQF) describes palliative care as “patient the practice of PHC. Role definition will include goals for and family-centered care that optimizes quality of life by an- providing services that establish general principles and best ticipating, preventing, and treating suffering . throughout practices in the care of this patient population. This docu- the continuum of illness . addressing the
    [Show full text]
  • Part 2 Drug Utilization Review Board
    Utah Code Part 2 Drug Utilization Review Board 26-18-101 Definitions. As used in this part: (1) "Appropriate and medically necessary" means, regarding drug prescribing, dispensing, and patient usage, that it is in conformity with the criteria and standards developed in accordance with this part. (2) "Board" means the Drug Utilization Review Board created in Section 26-18-102. (3) "Compendia" means resources widely accepted by the medical profession in the efficacious use of drugs, including "American Hospital Formulary Services Drug Information," "U.S. Pharmacopeia - Drug Information," "A.M.A. Drug Evaluations," peer-reviewed medical literature, and information provided by manufacturers of drug products. (4) "Counseling" means the activities conducted by a pharmacist to inform Medicaid recipients about the proper use of drugs, as required by the board under this part. (5) "Criteria" means those predetermined and explicitly accepted elements used to measure drug use on an ongoing basis in order to determine if the use is appropriate, medically necessary, and not likely to result in adverse medical outcomes. (6) "Drug-disease contraindications" means that the therapeutic effect of a drug is adversely altered by the presence of another disease condition. (7) "Drug-interactions" means that two or more drugs taken by a recipient lead to clinically significant toxicity that is characteristic of one or any of the drugs present, or that leads to interference with the effectiveness of one or any of the drugs. (8) "Drug Utilization Review" or "DUR" means the program designed to measure and assess, on a retrospective and prospective basis, the proper use of outpatient drugs in the Medicaid program.
    [Show full text]
  • Hospice Employees' Perceptions of Their Work Environment
    International Journal of Environmental Research and Public Health Article Hospice Employees’ Perceptions of Their Work Environment: A Focus Group Perspective Rebecca H. Lehto 1,* , Carrie Heeter 2, Jeffrey Forman 3, Tait Shanafelt 4, Arif Kamal 5, Patrick Miller 6 and Michael Paletta 6 1 College of Nursing, Michigan State University, East Lansing, MI 48824, USA 2 Department of Media and Information, Communication Arts & Sciences, Michigan State University, East Lansing, MI 48824; [email protected] 3 Former Medical Director of Development, Karmanos Cancer Institute, Detroit, MI 48201, USA; jeff[email protected] 4 Department of Medicine, Stanford University, Stanford, CA 94304, USA; [email protected] 5 Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC 27710, USA; [email protected] 6 Hospice of Michigan, 2366 Oak Valley Drive, Ann Arbor, MI 48103, USA; [email protected] (P.M.); [email protected] (M.P.) * Correspondence: [email protected] Received: 30 June 2020; Accepted: 17 August 2020; Published: 24 August 2020 Abstract: Burnout in healthcare professionals can lead to adverse effects on physical and mental health, lower quality of care, and workforce shortages as employees leave the profession. Hospice professionals are thought to be at particularly high risk for burnout. The purpose of the study was to evaluate workplace perceptions of interdisciplinary hospice care workers who provide care to patients at end of life. Six focus groups and one semi-structured interview were conducted with mixed group of social workers, managers, nurses, hospice aides, chaplains, support staff, and a physician (n = 19). Findings from the groups depicted both rewards and challenges of hospice caregiving.
    [Show full text]
  • Hospice-Hospital Collaborations: Making the Case to Hospital Administrators
    National Hospice and Palliative Care Organization Palliative Care Resource Series HOSPICE-HOSPITAL COLLABORATIONS: MAKING THE CASE TO HOSPITAL ADMINISTRATORS Todd Cote, MD INTRODUCTION As healthcare in our country continues to evolve, hospitals and hospital systems maintain their focus on quality improvement and accountability, now mandated through healthcare reform. Hospice and palliative care also continue on the quality improvement pathway. It is important for hospice and palliative care programs to align with the hospitals in providing the highest quality care to patient and families both within the hospital and once they have returned home. Strong sustainable collaborations will assure quality palliative and end-of-life care for both patients and families. This paper will present ways in which a hospice organization can align with hospital and hospital system administrators to provide or assist them in assuring quality care for patients approaching the end of life. CURRENT HOSPITAL ENVIRONMENT Hospitals and hospital administrators continue to focus on both internal (within hospital) and external (outside hospital) quality improvement (QI). This QI focus is an opportunity for hospice organizations to work directly with hospital administrators. Hospitals are keen to the value formula (Value= Quality/Cost) and thus are more interested in collaborating with outside organizations that can help both improve quality and decrease or contain cost. Although the hospital may be very mission-oriented, more and more hospitals are becoming data- driven. Increased focus on government mandates from health care reform such as re-admission rates, mortality index (observed deaths/expected deaths), and patient satisfaction ratings, has created opportunities for hospice organizations to contribute their expertise in the direct care of hospitalized and post-hospitalized patients and families.
    [Show full text]
  • Standards of Practice for Hospice Programs PROFESSIONAL DEVELOPMENT and RESOURCE SERIES
    STANDARDS OF PRACTICE FOR HOSPICE PROGRAMS PROFESSIONAL DEVELOPMENT AND RESOURCE SERIES 5 / Clinical Excellence and Safety (CES) 36 PROFESSIONAL DEVELOPMENT AND RESOURCE SERIES 5 / Clinical Excellence and Safety (CES) PRINCIPLES • The hospice ensures clinical excellence and safety promotion through standards of practice. • The desired outcomes of hospice interventions are for patients to feel safe and comfortable throughout the dying process; and for patients and families to feel supported and have adequate information appropriate to their needs throughout the trajectory of the illness, the dying experience, and for the first year or longer after the death. Hospice outcomes are individualized through a collaborative and reiterative process between the hospice interdisciplinary team and the patient/family/caregiver system. This process includes continuous assessment and identification of the goals, needs, strengths, and wishes of the patient and family/caregiver. • The hospice provides for the safety of all staff while promoting the development and maintenance of a safe environment for patients and families/caregivers served. Standard: CES 1: The comprehensive assessment performed by the hospice interdisciplinary team and the patient’s goals for care serve as the basis for the development of the patient’s plan of care. CES 1.1 Initial information documenting the patient’s terminal prognosis and principle diagnosis, as well as contributory and secondary diagnoses, is obtained and reviewed prior to admission to hospice services. CES 1.2 The hospice nurse makes an initial assessment within 48 hours of the effective date of the patient’s hospice election statement. CES 1.3 The hospice interdisciplinary team, in consultation with the patient’s attending physician, completes the comprehensive assessment within five calendar days of the effective date of the hospice election statement.
    [Show full text]
  • The Affordable Care Act and End of Life Care: Executive Summary Introduction It Is Estimated That More Than 1,500 People Will Di
    The Affordable Care Act and End of Life Care: Executive Summary Introduction It is estimated that more than 1,500 people will die from cancer each day in 2011, which will result in approximately 570,000 lives lost for the year.i With one in four people dying as a result of this disease, there is a need to demand better and more efficient use and coverage for end of life care. The goal to maintain the best quality of life should be one for every patient diagnosed with cancer. Research shows, however, that people with a terminal diagnosis often either do not receive palliative care or hospice or, if offered, it is too late in the course of the disease to make an impact.ii The Institute of Medicine in its report Palliative Care for Cancer notes that half of people dying of cancer suffer from a number of symptoms including pain, labored breathing, distress, nausea, confusion and other physical or psychological conditions that go untreated or undertreated and vastly diminish the quality of their remaining days.iii Unfortunately, cancer is a disease that also affects the family and caregivers of patients, and the impact of this suffering during the dying process is reported to have an immense emotional and financial burden on them.iv Cancer also has a burdensome effect on our health care system. With the overwhelming majority of cancer patients over the age of 55, the cost of care poses the greatest impact to the Medicare payer system. This program pays for the health care services provided to approximately 80 percent of all individuals who die in the United States.v It is well documented that Medicare expenditures increase substantially during the last year of life.
    [Show full text]
  • Drug Utilization Review Drug Utilization Review (DUR) Board
    Bruce Rauner, Governor Felicia F. Norwood, Director 201 South Grand Avenue East Telephone: (217) 782-1200 Springfield, Illinois 62763-0002 TTY: (800) 526-5812 Drug Utilization Review Drug Utilization Review (DUR) Board Federal regulations at 42 C.F.R. § 456.703 - 456.725 require that state Medicaid pharmacy programs establish and maintain a Drug Utilization Review (DUR) program that helps ensure appropriate drug utilization by conducting prospective and retrospective drug utilization review, and maintaining an educational program. Prospective Drug Utilization Review (DUR) Prospective Drug Utilization Review occurs at point-of-sale. Pharmacists review drug therapy at point-of-sale to screen for therapeutic duplication, drug-disease contraindication, adverse drug-drug interactions, incorrect drug doses or durations of therapy, drug allergy interactions, and clinical abuse/misuse. Pharmacists then counsel HFS clients regarding their medications according to state standards. Claims processing edits and prior authorization criteria for medications can impact this process. Prior approval status of a medication is searchable at http://ilpriorauth.com/. Retrospective Drug Utilization Review Retrospective DUR periodically evaluates drug claims data and other records to monitor for fraud, therapeutic appropriateness, overutilization and underutilization, appropriate use of generic products, therapeutic duplication, drug-disease contraindication, drug-drug interactions, incorrect drug dosage, incorrect duration of drug therapy, and clinical abuse
    [Show full text]
  • Prescription Drug Benefit Manual Chapter 7 – Medication Therapy Management and Quality Improvement Program
    Prescription Drug Benefit Manual Chapter 7 – Medication Therapy Management and Quality Improvement Program Table of Contents (Rev. 11, 02-19-10) Transmittals for Chapter 7 10 – Medication Therapy Management and Quality Improvement Program 10.1 Introduction 10.2 Definition of Terms 20 – Quality Assurance Requirements 20.1 – General Rule 20.2 – Compliance With State Standards 20.3 – Concurrent Drug Utilization Review (DUR) 20.4 – Retrospective Drug Utilization Review (RDUR) 20.5 – Medication Error Identification and Reduction (MEIR) 20.6 – Medwatch Reporting 20.7 – CMS Performance Measures 20.8 – Information for Quality Improvement Organizations (QIOs) 30 – Medication Therapy Management Program (MTMP) 30.1 – General Rule 30.2 – Targeted Beneficiaries 30.3 – MTM Services 30.4 – Use of Experts 30.5 – Considerations in MTMP Fees 30.6 – MTMP Application 30.7 – MTMP Approval Considerations 30.8 – Mid–Year MTMP Changes 30.9 – MTMP Reporting 30.10 - Claims Processing for MTM Services 40 – Consumer Satisfaction Surveys 40.1 – General Rule 40.2 – Part D Sponsor Follow-up Responsibilities 50 – Electronic Prescription Program (E-prescribing) 50.1 – General Rule 50.2 – State Law Preemption 50.3 – Standards for E-Prescribing 50.4 – Exemptions 50.5 – Promotion of Electronic Prescribing by MA-PD Plans 60 – Drug Utilization Management Program 60.1 – General Rule 60.2 – Over-the-Counter Drugs as Part of Utilization Management Programs 60.3 – Exception for Private Fee-for-Service MA Plans 60.4 – Drug Utilization Management Disclosure Requirements 60.5 – Web site Posting Requirements 60.6 – Revision of Utilization Management Criteria Requirements 70 - Part D Complaints Processing 70.1 – General Rule 70.2 – Timeframes for Complaints Processing Appendix A – Chapter 7 Related Web Sites 10 – Medication Therapy Management and Quality Improvement Program (Rev.
    [Show full text]
  • Drug Utilization Review (DUR) Solutions
    Conduent Health Government Healthcare Solutions Drug Utilization Review (DUR) Solutions Control pharmacy costs with automated clinical support. With ever-increasing medication costs, appropriate use means more than ensuring patient safety. Duplicated or overprescribed therapies leave you with fewer resources to serve members and improve population health. Program guidelines help providers prescribe clinically sound, cost- effective medications, but enforcing them with equally applied interventions can be just as costly. Is there a better way to improve guideline adherence and control program costs? With Drug Utilization Review (DUR) solutions from Conduent, your program can promote clinical safety, therapeutic efficacy and appropriate drug use more efficiently. Our online ProDUR solutions review and analyze prescriptions in real time against predetermined clinical criteria, helping you improve adherence to your guidelines and conserving your budget. And our RetroDUR programs monitor sub- optimal therapies and provide the basis for population-based interventions that educate prescribers, generating more savings over the long term. Our approach improves care quality and your population’s health while saving your program’s valuable resources. ProDUR: Prevent Issues Early with Prospective DUR The more your providers’ prescribing patterns align with evidence- based drug utilization standards, the less likely their prescriptions will require a revision or costly intervention when dispensed. This can be difficult as these standards update continually for the most appropriate use. That’s why our ProDUR solutions provide comprehensive clinical decision support that changes with your needs. 1 of 3 Conduent Health Government Healthcare Solutions We use a parameter-driven web-based interface that enables you to modify edits quickly and simply, with no programming experience required – authorized users can simply log on and make desired changes.
    [Show full text]